十一月 2025
- Home
- Dr. Reddy's Laboratories
十一月 2025的Dr. Reddy's Laboratories市场份额分析
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas.
显示 Dr. Reddy's Laboratories 主网站(包括公司地区网站)的流量和参与度信息
查看更多网站流量和参与度信息- drreddys.com
- msnlabs.com
- aurigeneservices.com
Dr. Reddy's Laboratories收入截至 十一月 2025为 25M - 50M
Dr. Reddy's Laboratories主要域名产生的收入
3 年中Dr. Reddy's Laboratories主要域名的收入
Dr. Reddy's Laboratories主要域名的收入
十一月 2025的Dr. Reddy's Laboratories股票价格
Dr. Reddy's Laboratories的股票交易代码为 RDY。您可以在下面查看过去 12 个月的Dr. Reddy's Laboratories股票表现(最多 十一月 2025)
Dr. Reddy's Laboratories热门域名的总访问量
了解Dr. Reddy's Laboratories市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Dr. Reddy's Laboratories热门域名的平均访问时长
分析Dr. Reddy's Laboratories参与度指标。
过去 3 个月的平均访问时长
子公司明细
Dr. Reddy's Laboratories热门域名的平均页面浏览量
了解Dr. Reddy's Laboratories如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Dr. Reddy's Laboratories 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Dr. Reddy’s Laboratories Ltd. is developing Eftilagimod Alfa.This agreement grants Dr Reddy's the rights to develop and commercialise Eftilagimod Alfa in countries outside North America, Europe, Japan, and Greater China.
十二月 9, 2025阅读更多
新闻Dr. Reddy’s Laboratories Ltd. partnered with Immutep Limited on Dec 8th '25.Dr Reddy's has signed an exclusive licensing deal with Australia's Immutep to make, develop and distribute the company's cancer treatment, according to a stock exchange filing on Monday.
十二月 8, 2025阅读更多
新闻Dr. Reddy’s Laboratories Ltd. received award Notice of Non-Compliance on Oct 29th '25.In a regulatory statement on Wednesday, Dr Reddy's Laboratories stated that the company had received a Notice of Non-Compliance (NON) from Canada's Pharmaceutical Drugs Directorate about its Semaglutide injection application, which requested additional information and clarifications.
十月 30, 2025阅读更多
查看 Dr. Reddy's Laboratories 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。